1
|
Chamberlain AER, Paterson KJ, Armstrong RJ, Twin HC, Donohoe TJ. A hydrogen borrowing annulation strategy for the stereocontrolled synthesis of saturated aza-heterocycles. Chem Commun (Camb) 2020; 56:3563-3566. [DOI: 10.1039/d0cc00903b] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
A hydrogen borrowing annulation strategy enables the stereocontrolled synthesis of C2, C3 and C4-substituted saturated aza-heterocycles.
Collapse
|
2
|
Collier PN, Twin HC, Knegtel RMA, Boyall D, Brenchley G, Davis CJ, Keily S, Mak C, Miller A, Pierard F, Settimo L, Bolton CM, Chiu P, Curnock A, Doyle E, Tanner AJ, Jimenez JM. Discovery of Selective, Orally Bioavailable Pyrazolopyridine Inhibitors of Protein Kinase Cθ (PKCθ) That Ameliorate Symptoms of Experimental Autoimmune Encephalomyelitis. ACS Med Chem Lett 2019; 10:1134-1139. [PMID: 31417666 DOI: 10.1021/acsmedchemlett.9b00134] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2019] [Accepted: 06/27/2019] [Indexed: 11/28/2022] Open
Abstract
PKCθ plays an important role in T cell biology and is a validated target for a number of disease states. A series of potent and selective PKCθ inhibitors were designed and synthesized starting from a HTS hit compound. Cell activity, while initially a challenge to achieve, was built into the series by transforming the nitrile unit of the scaffold into a primary amine, the latter predicted to form a new hydrogen bond to Asp508 near the entrance of the ATP binding site of PKCθ. Significant improvements in physiochemical parameters were observed on introduction of an oxetane group proximal to a primary amine leading to compound 22, which demonstrated a reduction of symptoms in a mouse model of multiple sclerosis.
Collapse
Affiliation(s)
- Philip N. Collier
- Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | | | | | | | | | | | | | | | | | | | | | | | | | | | - Elisabeth Doyle
- Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | | | | |
Collapse
|
3
|
Jimenez JM, Boyall D, Brenchley G, Collier PN, Davis CJ, Fraysse D, Keily SB, Henderson J, Miller A, Pierard F, Settimo L, Twin HC, Bolton CM, Curnock AP, Chiu P, Tanner AJ, Young S. Design and Optimization of Selective Protein Kinase C θ (PKCθ) Inhibitors for the Treatment of Autoimmune Diseases. J Med Chem 2013; 56:1799-810. [DOI: 10.1021/jm301465a] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- Juan-Miguel Jimenez
- Department of Chemistry and ‡Department of Biology, Vertex Pharmaceuticals (Europe) Ltd., 88 Milton Park, Abingdon, Oxfordshire OX14 4RY, U.K
| | - Dean Boyall
- Department of Chemistry and ‡Department of Biology, Vertex Pharmaceuticals (Europe) Ltd., 88 Milton Park, Abingdon, Oxfordshire OX14 4RY, U.K
| | - Guy Brenchley
- Department of Chemistry and ‡Department of Biology, Vertex Pharmaceuticals (Europe) Ltd., 88 Milton Park, Abingdon, Oxfordshire OX14 4RY, U.K
| | - Philip N. Collier
- Department of Chemistry and ‡Department of Biology, Vertex Pharmaceuticals (Europe) Ltd., 88 Milton Park, Abingdon, Oxfordshire OX14 4RY, U.K
| | - Christopher J. Davis
- Department of Chemistry and ‡Department of Biology, Vertex Pharmaceuticals (Europe) Ltd., 88 Milton Park, Abingdon, Oxfordshire OX14 4RY, U.K
| | - Damien Fraysse
- Department of Chemistry and ‡Department of Biology, Vertex Pharmaceuticals (Europe) Ltd., 88 Milton Park, Abingdon, Oxfordshire OX14 4RY, U.K
| | - Shazia B. Keily
- Department of Chemistry and ‡Department of Biology, Vertex Pharmaceuticals (Europe) Ltd., 88 Milton Park, Abingdon, Oxfordshire OX14 4RY, U.K
| | - Jaclyn Henderson
- Department of Chemistry and ‡Department of Biology, Vertex Pharmaceuticals (Europe) Ltd., 88 Milton Park, Abingdon, Oxfordshire OX14 4RY, U.K
| | - Andrew Miller
- Department of Chemistry and ‡Department of Biology, Vertex Pharmaceuticals (Europe) Ltd., 88 Milton Park, Abingdon, Oxfordshire OX14 4RY, U.K
| | - Francoise Pierard
- Department of Chemistry and ‡Department of Biology, Vertex Pharmaceuticals (Europe) Ltd., 88 Milton Park, Abingdon, Oxfordshire OX14 4RY, U.K
| | - Luca Settimo
- Department of Chemistry and ‡Department of Biology, Vertex Pharmaceuticals (Europe) Ltd., 88 Milton Park, Abingdon, Oxfordshire OX14 4RY, U.K
| | - Heather C. Twin
- Department of Chemistry and ‡Department of Biology, Vertex Pharmaceuticals (Europe) Ltd., 88 Milton Park, Abingdon, Oxfordshire OX14 4RY, U.K
| | - Claire M. Bolton
- Department of Chemistry and ‡Department of Biology, Vertex Pharmaceuticals (Europe) Ltd., 88 Milton Park, Abingdon, Oxfordshire OX14 4RY, U.K
| | - Adam P. Curnock
- Department of Chemistry and ‡Department of Biology, Vertex Pharmaceuticals (Europe) Ltd., 88 Milton Park, Abingdon, Oxfordshire OX14 4RY, U.K
| | - Peter Chiu
- Department of Chemistry and ‡Department of Biology, Vertex Pharmaceuticals (Europe) Ltd., 88 Milton Park, Abingdon, Oxfordshire OX14 4RY, U.K
| | - Adam J. Tanner
- Department of Chemistry and ‡Department of Biology, Vertex Pharmaceuticals (Europe) Ltd., 88 Milton Park, Abingdon, Oxfordshire OX14 4RY, U.K
| | - Stephen Young
- Department of Chemistry and ‡Department of Biology, Vertex Pharmaceuticals (Europe) Ltd., 88 Milton Park, Abingdon, Oxfordshire OX14 4RY, U.K
| |
Collapse
|
4
|
Charrier JD, Miller A, Kay DP, Brenchley G, Twin HC, Collier PN, Ramaya S, Keily SB, Durrant SJ, Knegtel RMA, Tanner AJ, Brown K, Curnock AP, Jimenez JM. Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors. J Med Chem 2011; 54:2341-50. [PMID: 21391610 DOI: 10.1021/jm101499u] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
Interleukin-2 inducible T-cell kinase (Itk) plays a role in T-cell functions, and its inhibition potentially represents an attractive intervention point to treat autoimmune and allergic diseases. Herein we describe the discovery of a series of potent and selective novel inhibitors of Itk. These inhibitors were identified by structure-based design, starting from a fragment generated de novo, the 3-aminopyrid-2-one motif. Functionalization of the 3-amino group enabled rapid enhancement of the inhibitory activity against Itk, while introduction of a substituted heteroaromatic ring in position 5 of the pyridone fragment was key to achieving optimal selectivity over related kinases. A careful analysis of the hydration patterns in the kinase active site was necessary to fully explain the observed selectivity profile. The best molecule prepared in this optimization campaign, 7v, inhibits Itk with a K(i) of 7 nM and has a good selectivity profile across kinases.
Collapse
Affiliation(s)
- Jean-Damien Charrier
- Department of Chemistry, Vertex Pharmaceuticals (Europe) Ltd., 88 Milton Park, Abingdon, Oxfordshire OX14 4RY, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
L. Pinder J, J. Durrant S, Charrier JD, Jimenez JM, Brenchley G, N. Collier P, Kay D, Miller A, Pierard F, Ramaya S, Sadiq S, C. Twin H. Synthesis of a Stable Pyridyl Boronate and Its Reaction with Aryl and Heteroaryl Halides. HETEROCYCLES 2006. [DOI: 10.3987/com-06-s(w)54] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|